Minimal residual disease in chronic myeloid leukaemia patients

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 159-178

  Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL; Chronic myeloid leukaemia; Interferon alpha; Minimal residual disease; Real time PCR; ST1571; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; GAMMA INTERFERON; RNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; HUMAN; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; WESTERN BLOTTING; ALLOGENEIC STEM CELL TRANSPLANTATION; CHIMERA; REVIEW; CHROMOSOME ANALYSIS; GENETICS; MYELOID LEUKEMIA;

CYTOGENETIC ANALYSIS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0036009612     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0190     Document Type: Article

References (97)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosome abnormality in chronic myelogenous leukaemia detected by quinacrine fluorescence and Giemsa staining
3. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
4. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia
5. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
6. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
7. Current aspects of drug therapy in Philadelphia-positive CML: Correlation of tumor burden with survival
8. Exclusion of chromosomal mosaicism: Tables of 90%, 95%, and 99% confidence limits and comments on use
9. Suppression on cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
10. Correlation between chromosomal abnormalities and blast-phenotype in the blast crisis of Ph-positive CGL
11. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization
12. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia
13. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques
14. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
15. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: Comparison with metaphase banding analysis
16. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in-situ hybridization
17. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-α therapy
18. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients
19. Autologous transplantation of in vivo purged PBSC in CML: Comparison of FISH, cytogenetics, and PCR for detection of Philadelphia chromosome in leukapheresis products
20. +/CD38lo population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization
21. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system
22. A multicenter investigation with D-FISH BCR/ABLI probes
23. Frequent deletion of hSNF5/INII, a component of the SWI/SNF complex, during progression of chronic myeloid leukemia
24. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
25. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia
26. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis
27. bcr rearrangement: Potential false positive secondary to an ECORI restriction fragment length polymorphism
28. Multiple restriction enzyme digests are required to rule out polymorphism in the molecular diagnosis of chronic myeloid leukemia
29. Frequent and extensive deletion during the 9,22 translocation in CML
30. Philadelphia-positive chronic myelogenous leukemia with breakpoint 5′ of the breakpoint cluster region but within the bcr gene
31. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia
32. Value of molecular monitoring during treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B Study
33. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia
34. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia
35. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients
36. Polymerase chain reaction for detection of residual leukaemia
37. Significance of residual leukaemia transcripts after bone marrow transplant for CML
38. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
39. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
40. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders
41. P190BCR-ABL chronic myeloid leukaemia: The missing link with chronic myelomonocytic leukaemia?
42. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment
43. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
44. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
45. Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: A report on 38 consecutive cases
46. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
47. Competitive PCR to monitor residual disease after bone marrow transplantation for chronic myeloid leukaemia
48. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: An updated meeting report and review
49. Long-term follow-up of patients after related-and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia
50. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation
51. Minimal residual disease in CML
52. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α
53. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy
54. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity
55. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
56. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biological significance and implications for the assessment of minimal residual disease
57. The molecular biology of chronic myeloid leukaemia
58. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
59. Exon-skipping in BCR-ABL is induced by ABL exon 2
60. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation
61. BCR-ABL detection precede cytogenetic relapse
62. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
63. Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR)
64. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction
65. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease
66. Current recommendations for positive controls in RT-PCR assays
67. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
68. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
69. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia
70. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
71. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
72. Durability of response following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
73. On behalf of the Chronic Leukemia Working Committee of the IBMTR. Recommendations for assessment and definitions of response and relapse in CML: A report from the Chronic Leukemia Working Committee of the IBMTR
74. Molecular remission in chronic myeloid leukaemia following a non-ablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect
75. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection cells for autografting in chronic myelogenous leukemia
76. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft
77. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myeloid leukemia: Low levels of minimal residual disease are associated with continuing remission
78. BCR-ABL positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-α
79. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay
80. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation
81. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
82. Continuous fluorescence monitoring of rapid cycle DNA amplification
83. The LightCycle™: A microvolume multisample fluorimeter with rapid temperature control
84. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
85. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia
86. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
87. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
88. Glivec™ (Imatinib mesylate, ST1571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in late chronic phase: Results of a phase II study
89. Glivec™ (Imatinib mesylate, ST1571) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a multicenter phase II study
90. Response monitoring in CML patients treated with the tyrosine kinase inhibitor ST1571 (GlivecR) by molecular cytogenetics and quantitative RT-PCR
91. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases
92. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction
93. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification or short tandem repeat-markers
94. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats
95. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation
96. Quality assurance in RT-PCR-based BCR/ABL diagnostics - Results of an interlaboratory test and a standardization approach
97. Optimizing sensitivity and reliability of detection and quantification of residual disease in CML patients by real-time PCR